Home » Newsletters » The Carlat Psychiatry Report

The Carlat Psychiatry Report

Schizophrenia (March) | 2014

View Archived Issues

Glutamate’s Role in Schizophrenia

March 1, 2014

There’s a rich history of research suggesting that glutamate may be involved in the pathogenesis of schizophrenia, with an increasing amount of attention being brought to glutamate during the past decade or so. Read More

Beyond Medication: Nonpharmacological Treatments for Schizophrenia

March 1, 2014

Rachel Loewy, PhD

Rachel Loewy, PhD, explores evidence-based psychosocial interventions for schizophrenia: CBT, multifamily group therapy, supported employment, and cognitive remediation. Read More

Is Treating Depression Good for the Heart?

March 1, 2014

Depression is a known risk factor for cardiovascular disease (CVD), but, surprisingly, it’s not known whether effectively treating depression can reduce the risk of a future cardiovascular event in depressed patients without preexisting CVD. Read More

Psychiatric Symptoms, Not Diagnoses, Have Most Effect on Work

March 1, 2014

Section editor, Glen Spielmans, PhD

Psychiatric disorders account for billions of dollars of costs related to absenteeism, reduced productivity, and treatment each year. Most research in this area has focused on standard DSM diagnoses, but it may be more informative to look instead at psychiatric symptoms, such as insomnia and emotional distress, and their effect on the workplace. Read More

Children of Young Moms or Old Dads Most Likely to Develop Psychiatric Disorders

March 1, 2014

People born to women between the ages of 12 and 19 or to men over the age of 45 are at the greatest risk for developing psychiatric disorders, according to the results of a Danish population-based study of close to three million people born between 1955 and 2006. Read More

Vitamin E May Slow Progress of Alzheimer’s

March 1, 2014

Recent research published in the Journal of the American Medical Association (JAMA) found that vitamin E slowed functional decline in Alzheimer’s disease better than memantine (Namenda) (Dysken MW et al, JAMA 2014;311(1):33-44). Read More